| scholarly article | Q13442814 |
| P50 | author | Ricard Cervera i Segura | Q53547424 |
| Carlos Vasconcelos | Q56750258 | ||
| Maria Giovanna Danieli | Q58128912 | ||
| Yair Levy | Q73255332 | ||
| Josep Font | Q73474655 | ||
| Mauro Galeazzi | Q73480279 | ||
| Gian Domenico Sebastiani | Q77434471 | ||
| Haner Direskeneli | Q88366048 | ||
| Roberto Cattaneo | Q88591752 | ||
| Daniel Blockmans | Q88953452 | ||
| Frederic A Houssiau | Q90710486 | ||
| Ahmet Gul | Q92474749 | ||
| Alessandro Mathieu | Q114314184 | ||
| Enrique de Ramon Garrido Ed | Q114416244 | ||
| Daniel Abramovicz | Q114416245 | ||
| Rajko Popovic | Q114416246 | ||
| Renato Alberto Sinico | Q114416247 | ||
| Geneviève Depresseux | Q114416248 | ||
| Jean-Pierre Cosyns | Q114416249 | ||
| P2093 | author name string | David D'Cruz | |
| Peter Petera | |||
| Radmila Petrovic | |||
| P2860 | cites work | Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis | Q34244145 |
| Effect of long-term normalization of serum complement levels on the course of lupus nephritis | Q41226267 | ||
| Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide | Q43993205 | ||
| Sequential therapies for proliferative lupus nephritis | Q44785533 | ||
| Maintenance therapy for lupus nephritis--something old, something new. | Q44785538 | ||
| P433 | issue | 12 | |
| P921 | main subject | patient | Q181600 |
| lupus nephritis | Q1621830 | ||
| P304 | page(s) | 3934-3940 | |
| P577 | publication date | 2004-12-01 | |
| P1433 | published in | Arthritis & Rheumatology | Q4797636 |
| P1476 | title | Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial | |
| P478 | volume | 50 |
| Q37577571 | A perspective on B-cell-targeting therapy for SLE. |
| Q31029893 | A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial |
| Q36951011 | Advances in lupus and Sjögren's syndrome: a tribute to Josep Font |
| Q36221407 | American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis |
| Q44371554 | An observational study of outcome in SLE patients with biopsy-verified glomerulonephritis between 1986 and 2004 in a defined area of southern Sweden: the clinical utility of the ACR renal response criteria and predictors for renal outcome |
| Q37270846 | Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus |
| Q58549171 | Anti-Double-Stranded DNA Isotypes and Anti-C1q Antibody Improve the Diagnostic Specificity of Systemic Lupus Erythematosus |
| Q34409787 | Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial |
| Q79839545 | Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial |
| Q38097129 | B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design |
| Q37371383 | Beyond immunosuppression - challenges in the clinical management of lupus nephritis |
| Q37167062 | Biomarkers and updates on pediatrics lupus nephritis |
| Q38425837 | Biomarkers in lupus nephritis |
| Q37038307 | Biomarkers of lupus nephritis determined by serial urine proteomics |
| Q49349531 | Causes and predictors of mortality in biopsy-proven lupus nephritis: the Sarawak experience |
| Q47218712 | Chronicity index, especially glomerular sclerosis, is the most powerful predictor of renal response following immunosuppressive treatment in patients with lupus nephritis. |
| Q49475768 | Clinical Outcomes Observed among Biopsy Proven Lupus Nephritis Patients Treated with Mycophenolate Mofetil as First-line Therapy |
| Q36752458 | Clinical features, epidemiology, and short-term outcomes of proliferative lupus nephritis in Eastern India |
| Q51775346 | Clinical outcomes of childhood lupus nephritis: a single center's experience. |
| Q50285114 | Clinical predictors of proteinuric remission following an LN flare - evidence from the UK JSLE cohort study |
| Q37168033 | Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future--the EULAR recommendations for the management of SLE and the use of end-points in clinical trials |
| Q36266807 | Clinicopathological findings, treatment response and predictors of long-term outcome in a cohort of lupus nephritis patients managed according to the Euro-lupus regime: a retrospective analysis in Sri Lanka |
| Q41540102 | Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis |
| Q36790809 | Current management of lupus nephritis: popular misconceptions |
| Q37168027 | Current treatment of lupus nephritis |
| Q46810854 | Defining the role of mycophenolate mofetil in the treatment of proliferative lupus nephritis. |
| Q91803887 | Delayed lupus nephritis in the course of systemic lupus erythematosus is associated with a poorer treatment response: a multicentre, retrospective cohort study in Japan |
| Q38059445 | Diagnosis and treatment of lupus nephritis flares--an update. |
| Q53644663 | Early achievement of complete renal response predicts good long-term renal outcome and low systemic damage in newly diagnosed lupus nephritis class III or IV. |
| Q51173136 | Efficacy and toxicity of treatments for nephritis in a series of consecutive lupus patients. |
| Q36922219 | Elderly-onset systemic lupus erythematosus: prevalence, clinical course and treatment |
| Q36634248 | Emerging drug therapies for systemic lupus erythematosus |
| Q30490276 | First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study. |
| Q30456024 | Genetic approach to study lupus glomerulonephritis |
| Q35854401 | Glomerular necrotic lesions and long-term outcomes among patients with proliferative lupus nephritis |
| Q58204623 | Glomerulomegaly in lupus nephritis: a prognostic marker for renal outcomes |
| Q81776040 | Glomerulonephritis |
| Q43004359 | Good outcomes with mycophenolate-cyclosporine-based induction protocol in children with severe proliferative lupus nephritis. |
| Q46019744 | Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide |
| Q57689077 | Immunosuppressive treatment for proliferative lupus nephritis |
| Q37671987 | Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis |
| Q80166845 | Induction therapy for active lupus nephritis: mycophenolate mofetil versus cyclophosphamide |
| Q37462538 | Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study |
| Q35971689 | Insulin-Like Growth Factor Binding Protein-4 as a Marker of Chronic Lupus Nephritis |
| Q42409898 | Intravenous immunoglobulin therapy in severe lupus myocarditis: good outcome in three patients |
| Q36302245 | Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis |
| Q39789199 | Long-term Outcome of Lupus Nephritis Class II in Argentine Patients: An Open Retrospective Analysis |
| Q36681801 | Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis |
| Q43031095 | Long-term outcomes--mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. |
| Q41616353 | Long-term renal outcomes in a cohort of 1814 Chinese patients with biopsy-proven lupus nephritis. |
| Q97545249 | Low-Grade Proteinuria Does Not Exclude Significant Kidney Injury in Lupus Nephritis |
| Q79298359 | Low-dose intra-venous cyclophosphamide therapy in a patient with neurological complications of Behçet's disease |
| Q95592748 | Lupus nephritis |
| Q40619112 | Lupus nephritis in Latin American patients: 10-year results from a single medical center in Argentina |
| Q44009719 | Maintenance therapy with mycophenolate mofetil for children with severe lupus nephritis after low-dose intravenous cyclophosphamide regimen |
| Q92354998 | Management of refractory lupus nephritis: challenges and solutions |
| Q37754815 | Management of systemic lupus erythematosus in Chinese patients |
| Q50513436 | Mizoribine, tacrolimus, and corticosteroid combination therapy successfully induces remission in patients with lupus nephritis. |
| Q38409344 | Molecular evaluation of renal biopsies: a search for predictive and prognostic markers in lupus nephritis |
| Q42638034 | Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). |
| Q43061715 | Mycophenolate mofetil for lupus nephritis |
| Q37290624 | Mycophenolate mofetil in the treatment of lupus nephritis. |
| Q34975939 | Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis |
| Q36458168 | Mycophenylate mofetil: what role in the treatment of lupus? |
| Q90412368 | New therapeutic strategies in systemic lupus erythematosus management |
| Q36915693 | New treatment strategies for proliferative lupus nephritis: keep children in mind! |
| Q57213853 | Non-albumin proteinuria as a parameter of tubulointerstitial inflammation in lupus nephritis |
| Q37754557 | Novel approaches to therapy for systemic lupus erythematosus: update 2005. |
| Q36577362 | Optimum therapeutic approaches for lupus nephritis: what therapy and for whom? |
| Q64235419 | Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis |
| Q38123242 | Overview of lupus nephritis management guidelines and perspective from Asia |
| Q38175076 | Overview of lupus nephritis management guidelines and perspective from Asia. |
| Q37850999 | Pediatric SLE--towards a comprehensive management plan |
| Q60173972 | Pediatric lupus nephritis |
| Q57805128 | Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis |
| Q90177663 | Prediction of prognosis and renal outcome in lupus nephritis |
| Q51063607 | Predictive factors for low rate of remission in a population of Colombian patients with severe proliferative lupus nephritis. |
| Q84145951 | Predictive value of remission status after 6 months induction therapy in patients with proliferative lupus nephritis: a retrospective analysis |
| Q41552872 | Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort |
| Q38453113 | Predictors of renal relapse in Korean patients with lupus nephritis who achieved remission six months following induction therapy |
| Q39758027 | Pro: Cyclophosphamide in lupus nephritis |
| Q53098900 | Prognosis of proliferative lupus nephritis subsets in the Louvain Lupus Nephritis inception Cohort. |
| Q64983842 | Prognostic Factors for Clinical Response in Systemic Lupus Erythematosus Patients Treated by Allogeneic Mesenchymal Stem Cells. |
| Q36477390 | Prognostic value of anti-CRP antibodies in lupus nephritis in long-term follow-up |
| Q50984321 | Pulse cyclophosphamide induction treatment in Thai children with diffuse proliferative lupus nephritis. |
| Q35626485 | Random spot urine protein/creatinine ratio: a reliable method for monitoring lupus nephritis? |
| Q41599627 | Remission of proteinuria indicates good prognosis in patients with diffuse proliferative lupus nephritis |
| Q36697845 | Renal Biopsy: A much needed tool in patients with Systemic Lupus Erythematosis (SLE). |
| Q39204673 | Renal outcomes among Egyptian lupus nephritis patients: a retrospective analysis of 135 cases from a single centre. |
| Q38833873 | Rethinking biologics in lupus nephritis |
| Q38831841 | Risk factors to predict the development of chronic kidney disease in patients with lupus nephritis |
| Q42597354 | Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis |
| Q36634902 | Role of serum anti-C1q antibodies as a biomarker for nephritis activity in pediatric and adolescent Egyptian female patients with SLE |
| Q37328887 | Serum IL-18 as biomarker in predicting long-term renal outcome among pediatric-onset systemic lupus erythematosus patients. |
| Q87705292 | Short-interval lower-dose intravenous cyclophosphamide as induction and maintenance therapy for lupus nephritis: a prospective observational study |
| Q45952883 | Strategy for second kidney biopsy in patients with lupus nephritis. |
| Q55933861 | Systemic lupus erythematosus |
| Q24543555 | Systemic lupus erythematosus |
| Q39053129 | Systemic lupus erythematosus diagnosis and management |
| Q43004356 | Tacrolimus is an alternative therapeutic option for the treatment of refractory lupus nephritis |
| Q41212927 | The Impact of Baseline Serum Creatinine on Complete Remission Rate and Long-Term Outcome in Patients with Severe Lupus Nephritis |
| Q38285375 | The multifaceted aspects of refractory lupus nephritis |
| Q26851705 | Therapeutic regulation of complement in patients with renal disease - where is the promise? |
| Q36084894 | Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients |
| Q36790803 | Thirty years of cyclophosphamide: assessing the evidence |
| Q48878229 | Thirty years, five hundred patients: some lessons learned from running a lupus clinic |
| Q24202572 | Treatment for lupus nephritis |
| Q36118534 | Treatment for lupus nephritis: a revisit |
| Q84127283 | Treatment of lupus nephritis |
| Q42728756 | Treatment of lupus nephritis |
| Q37822658 | Treatment of proliferative lupus nephritis: a slowly changing landscape |
| Q38271125 | Treatment of severe lupus nephritis: the new horizon. |
| Q37690745 | Update on emerging drug therapies for systemic lupus erythematosus |
| Q37255744 | Update on the management of lupus nephritis: let the treatment fit the patient |
| Q51813982 | Urinary TNF-like weak inducer of apoptosis (TWEAK) as a biomarker of lupus nephritis. |
| Q36666936 | Value of a complete or partial remission in severe lupus nephritis |
| Q84600171 | [Immunosuppresive treatment in patients with lupus glomerulonephritis. Review of adverse events] |
| Q85589119 | [Lupusnephritis] |
| Q84566584 | [Systemic lupus erythematosus. A problem based approach] |
Search more.